Oncolytic and Local Immunotherapy

Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
Jacob P van Vloten, Kathy Matuszewska, Mark A A Minow, Jessica A Minott, Lisa A Santry, Madison Pereira, Ashley A Stegelmeier, Thomas M McAusland, Elaine M Klafuric, Khalil Karimi, Joseph Colasanti, D Grant McFadden, James J Petrik, Byram W Bridle, Sarah K Wootton

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004335; DOI: 10.1136/jitc-2021-004335
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del Pozo, Jaime Martínez de Villarreal, Francisco X Real, Noemí Vidal, Gabriel Capella, Ramon Alemany, Emma Blasi, Carmen Blasco, Manel Cascalló, Ramon Salazar

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003255; DOI: 10.1136/jitc-2021-003255
Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
Bin-Jin Hwang, Li-Chung Tsao, Chaitanya R Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Takuya Osada, Herbert Kim Lyerly, Michael A Morse, Zachary Conrad Hartman

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003721; DOI: 10.1136/jitc-2021-003721
Oncolytic adenovirus decreases the proportion of TIM-3⁺ subset of tumor-infiltrating CD8⁺ T cells with correlation to improved survival in patients with cancer
Ilkka Liikanen, Saru Basnet, Dafne C A Quixabeira, Kristian Taipale, Otto Hemminki, Minna Oksanen, Matti Kankainen, Juuso Juhila, Anna Kanerva, Timo Joensuu, Siri Tähtinen, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003490; DOI: 10.1136/jitc-2021-003490
Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
Jianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie Liang, Yanli Guo, Juanjuan Ou

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003408; DOI: 10.1136/jitc-2021-003408
Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity
Jin-Yan Wang, Hengyu Chen, Shu-Zhen Dai, Feng-Ying Huang, Ying-Ying Lin, Cai-Chun Wang, Lei Li, Wu-Ping Zheng, Guang-Hong Tan

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003950; DOI: 10.1136/jitc-2021-003950
Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models
Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, Francesca Barone, Paul P Tak, Ghazaleh Tabatabai, James A Lederer, E Antonio Chiocca, Sean Lawler

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003368; DOI: 10.1136/jitc-2021-003368
Short-course neoadjuvant in situ vaccination for murine melanoma
Taylor J Aiken, David Komjathy, Matthew Rodriguez, Ashley Stuckwisch, Arika Feils, Vladimir Subbotin, Jen Birstler, Stephen D Gillies, Alexander L Rakhmilevich, Amy K Erbe, Paul M Sondel

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003586; DOI: 10.1136/jitc-2021-003586
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject ‘cold’ tumors
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur, Björn Frendéus

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003488; DOI: 10.1136/jitc-2021-003488
CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model
Ruikun Wang, Jingru Chen, Wei Wang, Zhuoqian Zhao, Haoran Wang, Shiyu Liu, Fan Li, Yajuan Wan, Jie Yin, Rui Wang, Yuanke Li, Cuizhu Zhang, Hongkai Zhang, Youjia Cao

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003809; DOI: 10.1136/jitc-2021-003809

Main menu

Oncolytic and Local Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic and Local Immunotherapy

Pages